A Phase i study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

Investigational New Drugs

Volumn 32, Issue 2, 2014, Pages 323-329

  Deming, Dustin A ^a   Ninan, Jacob ^a   Bailey, Howard H ^a   Kolesar, Jill M ^a   Eickhoff, Jens ^a   Reid, Joel M ^b   Ames, Matthew M ^b   McGovern, Renee M ^b   Alberti, Dona ^a   Marnocha, Rebecca ^a   Espinoza Delgado, Igor ^c   Wright, John ^c   Wilding, George ^a   Schelman, William R ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Phase I; PS 341; SAHA; Vorinostat

Indexed keywords

ALANINE AMINOTRANSFERASE; BORTEZOMIB; VORINOSTAT;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPONATREMIA; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MICTURITION DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SARCOMA; SENSORY NEUROPATHY; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRAZINES;

EID: 84896370460     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0035-8     Document Type: Article

References (15)

1. You JS, Jones PA (2012) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22(1):9-20
2. Toyota M, Suzuki H (2010) Epigenetics of genetic alterations. Adv Genet 70:309-323
3. Lambert MP, Herceg Z (2008) Epigenetics and cancer, 2nd IARC meeting, Lyon, France, 6 and 7 December 2007. Mon Oncol 2(1):33-40
4. Workman JL, Kingston RE (1998) Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67:545-579
5. Arts J, de Schepper S, Van Emelen K (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10:2343-2350
6. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428
7. Amin HM, Saeed S, Alkan S (2001) histone deacetylases inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15:17). Br J Haematol 115:287-297
8. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63:4460-4471
9. Marks PA, Xu WS (2009) Histone deacytlase inhibitors: potential in cancer therapy. J Cell Biochem 107:600-608
10. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S (2003) The proteosomes inhibitor bortezomib interacts synergistically with histone deacetylases inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 103:3765-3774
11. Sato A, Asano T, Ito K, Sumitomo M, Asano T (2011) Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJUI 109:1258-1268
12. Denlinger CE, Rundall BK, Jones DR (2004) Proteosome inhibitionsensitizes non-small cell lung cancer to histone deacetylase inhibitor - induced apoptosis through generation of reactive oxygen species. J Thoracic Cardiovasc Surg 128(5):740-748
13. Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, et al. A Phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. (Submitted)
14. Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ (2006) A liquid chromatography-electrospray ionization tandem mass spectrospray inonization tandem mass spectrometric assay for quantitation of the histone deacetylases inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chromatogr B Analyt Technol Biomde Life Sci 840(2):108-115
15. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG et al (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylases inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13(12):3605-3610